Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304751 | 0.87 | MPL (0.48) | MPLMAPTMAPK1ADORA3 | |
| SCHEMBL2300487 | 0.85 | ADORA3 (0.53) | MPLMAPTKDM4EPOLBADORA3 | |
| SCHEMBL2358584 | 0.83 | ADORA3 (0.51) | MPLADORA3 | |
| SCHEMBL2363666 | 0.80 | ADORA3 (0.50) | MAPTKDM4EADORA3LMNA | |
| SCHEMBL13328319 | 0.79 | ADORA3 (0.47) | MPLMAPTKDM4EPOLBADORA3 | |
| SCHEMBL3307894 | 0.79 | MLYCD (0.51) | MAPTKDM4ELMNA | |
| SCHEMBL13328313 | 0.79 | MPL (0.50) | MPLMAPTKDM4EADORA3CFTR | |
| SCHEMBL13364019 | 0.79 | PLTP (0.47) | MPLMAPTKDM4EPOLBADORA3 | |
| SCHEMBL13328316 | 0.79 | ADORA3 (0.50) | MPLMAPTKDM4EADORA3 | |
| SCHEMBL13328324 | 0.77 | ADORA3 (0.56) | MPLMAPTMAPK1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | MPL 1091/4885MAPT 4008/4885MAPK1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.